🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Pola bridging to CAR #18ICML - 200 pts: 122 polaBR, rest polaR - no diff in pre-CAR ORR with polaBR v polaR - more heme tox with BR - more ICANS w/ BR? tl;dr polaR just fine for bridging. #lymsm #tcellrx

One of the longest follow-up studies I've seen in DLBCL. Excess mortality from infection remains higher than general population for greater than 10 years. AML/MDS highest 1-4 yrs, lung & GI cancers 5-25 yrs. Cardiac deaths have fallen over time. #18ICML #lymsm

LEO/MER outcomes of sequential v concurrent transformed FL Carla Casulo, MD #18ICML: inferior EFS and OS with sequential transformation, and worst survival if transformation within 2 years. #lymsm

We are also interested in knowing and understanding this work more Let us know if we can participate in any way David Russler-Germain, MD/PhD Ajay Major, MD, MBA Jason Westin, MD FACP FASCO

thanks for sharing Ajay Major, MD, MBA

UBC study of DA-R-EPOCH in DHL (implemented provincewide in 2015). Superior TTP & OS with EPOCH vs RCHOP era. No difference in survival based on MYC Ig partner. OS worse with EPOCH if DZsig+. #18ICML #lymsm

I favor the same There is no high quality data in support of IT or IV CNS prophylaxis

ICML25: Outpatient fixed duration Mosun-Pola regimen is highly efficacious in 3L+ R/R MCL in this phase 2 cohort: 71% had 3+ high risk features (prior CAR, ASCT, TP53, Blastoid/pleomorphic, Ki67 30%+ etc). ORR 88%, CR79% CRS all low grade and resolved.

📢 Now available online ! Full article : Comparable response rates of venetoclax 50 mg with posaconazole versus venetoclax 400 mg despite lower pharmacokinetic exposure in newly diagnosed acute myeloid leukemia: less is enough 👉tandfonline.com/doi/full/10.10… #asco2025 poster,

Big news indeed

Our deeper dive on BMT CTN 1506 aka Morpho trial: FLT3-ITD/NPM1 co mutants with residual MRD uniquely benefit from #gilteratinib maintenance. FLT3-ITD/NPM1 co-mutation status may inform #alloHCT conditioning intensity decision #bmtsm #leusm ashpublications.org/bloodadvances/…

👉Here is an updated version of the Table which I initially posted post ASH2024. 👉Now Updated with EHA 2025 data including updated FLAIR, CLL13, CAPTIVATE trials. #CLL

In REACH3, ruxolitinib vastly improved failure-free survival (38.4 vs 5.7 months) over best therapy in steroid-refractory chronic GVHD, with durable responses and no new safety issues over 3 years. Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Excellent summary of #ICML2025 for R/R DLBCL ‘Three regimens. Three new paths forward. All better than what rituximab plus GemOx could offer’ POLARGO- STARGLO-SUNMO and then the newer DLBCL Classifiers LymphoMAP particularly of interest in the context of CAR-T efficacy

This is a major update Thank you dear Prof 🙏🏻

Very insightful report Lingaraj Nayak

Excellent paper by Sumeet Mirgh MD, DM et al Financial toxicity can be cut to 1% by replacing plerixafor with cyclophosphamide ± bortezomib And keeping the transplant outcomes similar! Practice changing, definitely! 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM Prashant Mehta Nico Gagelmann

The Kind Warrior’s Way – A Perspective The Kind Warrior is not one who battles others, but one who trains within. He sharpens his sword not for war, but for self-mastery. He builds his strength not to dominate, but to protect joy, integrity, and peace. This way of living does